Dare Bioscience, Inc. financial data

Symbol
DARE on Nasdaq
Industry
Pharmaceutical Preparations
Location
3655 Nobel Drive, Suite 260, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Cerulean Pharma Inc. (to 7/5/2017), Tempo Pharmaceuticals Inc (to 1/22/2008)
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 80.9 % -55.2%
Debt-to-equity -492 % -469%
Return On Equity 549 %
Return On Assets -140 % -101%
Operating Margin -1.01 K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 101 M shares +16.7%
Common Stock, Shares, Outstanding 101 M shares +16.7%
Entity Public Float 77.3 M USD -24.4%
Common Stock, Value, Issued 10.1 K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 101 M shares +17.5%
Weighted Average Number of Shares Outstanding, Diluted 101 M shares +17.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.82 M USD
Revenue from Contract with Customer, Excluding Assessed Tax 9.3 K USD
Research and Development Expense 19.8 M USD -32.2%
General and Administrative Expense 11.4 M USD -4.73%
Operating Income (Loss) -28.6 M USD +8.89%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -30.2 M USD +2.55%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -28.9 M USD +5.61%
Earnings Per Share, Basic -0.33 USD/shares +8.33%
Earnings Per Share, Diluted -0.33 USD/shares +8.33%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.63 M USD -81.6%
Accounts Receivable, after Allowance for Credit Loss, Current 10 M USD
Other Assets, Current 152 K USD -24.4%
Assets, Current 9.98 M USD -66.2%
Property, Plant and Equipment, Net 52.5 K USD -5.25%
Operating Lease, Right-of-Use Asset 1.56 M USD +324%
Other Assets, Noncurrent 655 K USD -18.1%
Assets 13 M USD -57.1%
Accounts Payable, Current 4.04 M USD +49.9%
Employee-related Liabilities, Current 805 K USD -53.2%
Accrued Liabilities, Current 1.37 M USD -75%
Contract with Customer, Liability, Current 205 K USD
Liabilities, Current 17.7 M USD -27.2%
Contract with Customer, Liability, Noncurrent 1 M USD 0%
Operating Lease, Liability, Noncurrent 1.17 M USD +1951%
Liabilities 24 M USD -5.45%
Accumulated Other Comprehensive Income (Loss), Net of Tax -400 K USD -7.18%
Retained Earnings (Accumulated Deficit) -178 M USD -19.4%
Stockholders' Equity Attributable to Parent -11 M USD -321%
Liabilities and Equity 13 M USD -57.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.81 M USD +57.7%
Net Cash Provided by (Used in) Financing Activities 14 K USD -98.9%
Net Cash Provided by (Used in) Investing Activities -7.3 K USD
Common Stock, Shares Authorized 240 M shares 0%
Common Stock, Shares, Issued 101 M shares +16.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.85 M USD +53.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.97 M USD -80%
Deferred Tax Assets, Valuation Allowance 112 M USD +7.71%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 112 M USD +7.71%
Operating Lease, Liability 1.64 M USD +318%
Depreciation 10.8 K USD +13.4%
Payments to Acquire Property, Plant, and Equipment 7.3 K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -28.9 M USD +6.17%
Lessee, Operating Lease, Liability, to be Paid 1.93 M USD +370%
Operating Lease, Liability, Current 470 K USD +40.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 680 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 660 K USD +610%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 284 K USD +1571%
Lessee, Operating Lease, Liability, to be Paid, Year Three 130 K USD
Deferred Tax Assets, Operating Loss Carryforwards 86.2 M USD +5.41%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 2.62 M USD +13%
Operating Lease, Payments 454 K USD +61%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.53 M USD +17.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%